Follow-The-Filings

Security · featured owners

VNDA Vanda Pharmaceuticals Inc.

COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 2.7%
  • $7M
  • 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 2.7% (Michael Krensavage - Krensavage Asset Management) · not free-float ownership

  1. Michael Krensavage 2.7%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Michael Krensavage - Krensavage Asset Management 2026 Q2 2.7% Hold 1,180,388 $7M history
Murray Stahl - Horizon Kinetics Asset Management 2026 Q2 <0.01% Reduce −4.6% 22,648 $139K history

2 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $192.64M $198.77M $216.1M
Net income $2.51M -$18.9M -$220.47M
Net margin * 1.3% -9.5% -102.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $432.95M $438.89M $347.26M
Total non-current assets * $215.49M $217.31M $141.69M
Total assets $648.44M $656.2M $488.95M
Total current liabilities $87.7M $99.98M $145.16M
Total non-current liabilities * $15.83M $17.68M $16.6M
Total equity $544.91M $538.55M $327.19M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $12.8M -$15.76M -$109.44M
Cash from investing -$12.06M -$17.43M $94.86M
Cash from financing $0M -$0.155M -$2.91M
Net change in cash $0.792M -$33.5M -$17.46M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders